Discseel involves injecting fibrin into a torn disc to seal it. The idea is sound. Here is what the published evidence does and does not show, including a placebo-controlled trial that failed.
Have you been looking into Discseel, an injection into the discs of the spine said to help with lower back pain? It comes up increasingly often in clinic, so let me explain what it actually involves and give you my honest assessment.
What it is
Discseel is the injection of a substance called fibrin into the lining of a disc believed to be causing your back pain.
The anatomy behind it
Your spine is made up of bones called vertebrae, with a disc acting as a cushion between each pair.
A disc has two components. The inner substance is the nucleus, which looks and feels much like a lump of crab meat, as the textbooks tend to describe it. Holding it in place is an outer lining of many layers called the annulus.
That annulus can tear. Sometimes disc material leaks out through the tear, but often it is liquid that escapes, causing inflammation and pain.
Keep that distinction between nucleus and annulus in mind, because it becomes important later.
Identifying the tear
If an MRI shows a disc with a small tear, dye can be injected into it under X-ray guidance to see whether the contrast leaks out, confirming the tear. With the patient awake during the injection, it can also be observed whether the pain is reproduced. This test is called a discogram.
The logic of the treatment
When you cut yourself and bleed, your blood produces fibrin. It forms a large part of the clot and the scab that prevents further bleeding, and it then breaks down gradually as the wound heals.
The idea behind Discseel is to inject fibrin into the torn outer lining so that, over time, it seals and heals.
It is a rational idea. The question is whether it works.
What the studies show
An early safety study examined 15 subjects who underwent the injection. Nine adverse effects were reported. The authors state that only two were directly related to the injection itself, but one of those was discitis, a serious infection of the disc which is notoriously difficult to treat.
A later study, published in Pain Physician, looked at patients with chronic lower back pain who had already failed other treatments, including previous surgery and injections. They received the Discseel injection and were followed up at one, two and three years.
The finding was that 50% of patients achieved the minimum improvement that could be classified as statistically significant.
How to read that figure
This needs careful interpretation, for two reasons.
First, the trial was conducted by the founders of Discseel. That does not invalidate it, but it is relevant context.
Second, consider what the headline figure actually means. Half the patients in the study did not notice a significant improvement in their pain. And of the half who did, what that means is that they barely crossed the minimum threshold that counts as statistically significant.
To their credit, the authors point out the shortfalls of the study themselves, particularly that it was not a randomised controlled trial comparing the treatment against a placebo.
But a placebo-controlled trial does exist
This is the part I think patients researching Discseel most need to know, because it rarely appears in the promotional material.
A Phase III randomised controlled trial of intradiscal fibrin sealant did take place, comparing it against a saline placebo in 220 patients. It was stopped early for lack of efficacy. At 26 weeks there was no difference between fibrin and saline on the primary outcome measure, and the results actually pointed slightly in favour of the saline.
A recent systematic review concluded that in adults with chronic discogenic low back pain, this form of fibrin injection does not reduce pain intensity or pain interference, and that adverse events are common and may not differ between fibrin and saline.
The counterargument, in fairness
Proponents of Discseel make a reasonable objection to my using that trial here, and you should weigh it.
They point out that the failed trial injected fibrin into the nucleus, the centre of the disc, whereas Discseel injects intra-annularly, into the torn outer lining itself. The formulation differed too, and so did patient selection. On that reading, the trial tested something related but not identical.
That is a legitimate distinction. My difficulty is that it leaves us where we started: the specific procedure being sold has still never been compared against a placebo, and the closest thing we have to that comparison failed.
One further consideration
There is a point I have made in previous videos that applies squarely here.
Any form of disc degeneration, whether an annular fissure, a disc bulge or a dark disc on MRI, is a very common finding in people who have no back pain at all. Studies scanning people without symptoms demonstrate this consistently.
So before treating a torn disc as the source of someone’s pain, we have to be confident it genuinely is.
My position
I do not want to appear dismissive of the researchers. Credit to them for pursuing the idea and for publishing their results with the limitations acknowledged.
But I would want to see a properly randomised, placebo-controlled trial of this specific procedure before I am willing to consider it for any of my own patients.
The key takeaway
The concept behind Discseel is logical. The published results in its favour come from studies run by its own founders, without a placebo comparison, showing half of patients barely reaching the threshold of significance.
Meanwhile, the one large placebo-controlled trial of intradiscal fibrin was halted for lack of benefit.
If you are considering this procedure, those are the questions worth putting to whoever is offering it.
